⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DWTX News
Dogwood Therapeutics, Inc. Common Stock
Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
accessnewswire.com
DWTX
DWTX
Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025
accessnewswire.com
DWTX
DWTX
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit
accessnewswire.com
DWTX
DWTX
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients
globenewswire.com
DWTX